Design Therapeutics, Inc.
About Design Therapeutics, Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$69.8M
- Total assets
- $226.2M
- Market cap
- $665.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $79.5M
- Operating income
- -$79.5M
- Income tax
- $0
- Net income
- -$69.8M
- EPS (basic)
- $-1.22
- EPS (diluted)
- $-1.22
Balance sheet
- Total assets
- $226.2M
- Current assets
- $223.8M
- Total liabilities
- $13.7M
- Current liabilities
- $13.1M
- Shareholders’ equity
- $212.5M
Cash flow
- Operating cash flow
- -$54.4M
- Investing cash flow
- $22.9M
- Financing cash flow
- $25.7M
- Net cash flow
- -$5.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $665.2M
- EPS (diluted)
- $-1.22
- Shares outstanding
- 62.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 26, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $69.8M in FY2025.
- Trading 32% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Design Therapeutics, Inc..
Write a review
News about Design Therapeutics, Inc.
News & sentiment via Polygon.io
